Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13625768 | 0.93 | ADORA3 (0.32) | ADORA3 | |
| SCHEMBL13625863 | 0.92 | ADORA3 (0.36) | ADORA3ADORA2A | |
| SCHEMBL13625862 | 0.91 | GRIN2B (0.34) | ADORA3ADORA2A | |
| SCHEMBL13625683 | 0.91 | ADORA3 (0.34) | ADORA3ADORA2A | |
| SCHEMBL13626076 | 0.91 | ADORA3 (0.34) | ADORA3ADORA2A | |
| SCHEMBL14393656 | 0.88 | ADORA3 (0.33) | ADORA3ADORA2A | |
| SCHEMBL14393622 | 0.84 | MGLL (0.31) | MGLLADORA2A | |
| SCHEMBL13819686 | 0.83 | MEN1 (0.31) | — | |
| SCHEMBL13625769 | 0.83 | GRIN2B (0.40) | CYP2D6 | |
| SCHEMBL14393617 | 0.83 | GRIN2B (0.32) | CYP2D6ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | CYP1A2 701/4885CYP2D6 1308/4885MGLL 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.